136 related articles for article (PubMed ID: 11569889)
21. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.
Lofters WS; Pater JL; Zee B; Dempsey E; Walde D; Moquin JP; Wilson K; Hoskins P; Guevin RM; Verma S; Navari R; Krook JE; Hainsworth J; Palmer M; Chin C
J Clin Oncol; 1997 Aug; 15(8):2966-73. PubMed ID: 9256141
[TBL] [Abstract][Full Text] [Related]
22. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Slabý J; Trnený M; Procházka B; Klener P
Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
[TBL] [Abstract][Full Text] [Related]
23. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
Aksoylar S; Akman SA; Ozgenç F; Kansoy S
Pediatr Hematol Oncol; 2001 Sep; 18(6):397-406. PubMed ID: 11554235
[TBL] [Abstract][Full Text] [Related]
24. Intravenous dolasetron mesilate ameliorates postoperative nausea and vomiting.
Diemunsch P; Leeser J; Feiss P; D'Hollander A; Bradburn BG; Paxton D; Whitmore J; Panouillot P; Navé S; Brown RA; Hahne WF
Can J Anaesth; 1997 Feb; 44(2):173-81. PubMed ID: 9043731
[TBL] [Abstract][Full Text] [Related]
25. Oral dolasetron mesylate for prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study. The Oral Dolasetron PONV Prevention Study Group.
Diemunsch P; Korttila K; Leeser J; Helmers JH; Wilkey B; Navé S; Radke AJ; Hahne WF; Brown RA
J Clin Anesth; 1998 Mar; 10(2):145-52. PubMed ID: 9524901
[TBL] [Abstract][Full Text] [Related]
26. Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery.
Balfour JA; Goa KL
Drugs; 1997 Aug; 54(2):273-98. PubMed ID: 9257083
[TBL] [Abstract][Full Text] [Related]
27. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.
Clemmons AB; Orr J; Andrick B; Gandhi A; Sportes C; DeRemer D
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2065-2071. PubMed ID: 29906570
[TBL] [Abstract][Full Text] [Related]
28. [Prophylaxis of nausea and vomiting after thyroid surgery: comparison of oral and intravenous dolasetron with intravenous droperidol and placebo].
Danner K; Becker HG; Best B; Madler C
Anasthesiol Intensivmed Notfallmed Schmerzther; 2001 Jul; 36(7):425-30. PubMed ID: 11496617
[TBL] [Abstract][Full Text] [Related]
29. Granisetron plus dexamethasone versus granisetron alone in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study.
Matsuoka S; Okamoto S; Watanabe R; Mori T; Nagayama H; Hamano Y; Yokoyama K; Takayama N; Ikeda Y
Int J Hematol; 2003 Jan; 77(1):86-90. PubMed ID: 12568305
[TBL] [Abstract][Full Text] [Related]
30. Intravenous dolasetron mesilate in the prevention of postoperative nausea and vomiting in females undergoing gynecological surgery.
Diemunsch P; D'Hollander A; Paxton L; Schoeffler P; Wessel P; Navé S; Brown RA; Hahne WF
J Clin Anesth; 1997 Aug; 9(5):365-73. PubMed ID: 9257201
[TBL] [Abstract][Full Text] [Related]
31. Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy.
Coppes MJ; Lau R; Ingram LC; Wiernikowski JT; Grant R; Howard DR; Perrotta M; Barr R; Dempsey E; Greenberg ML; Leclerc JM
Med Pediatr Oncol; 1999 Aug; 33(2):99-105. PubMed ID: 10398184
[TBL] [Abstract][Full Text] [Related]
32. An open-label dose comparison study of ondansetron for the prevention of emesis associated with chemotherapy prior to bone marrow transplantation.
Osowski CL; Dix SP; Lynn M; Davidson T; Cohen L; Miyahara T; Sexauer MC; Joyce R; Yeager A; Wingard JR
Support Care Cancer; 1998 Nov; 6(6):511-7. PubMed ID: 9833299
[TBL] [Abstract][Full Text] [Related]
33. A randomized, placebo-controlled pilot trial of aprepitant combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients undergoing cyclophosphamide-based conditioning regimens prior to hematopoietic stem cell transplant (HSCT).
Bubalo J; Mulverhill K; Meyers G; Hayes-Lattin B; Maziarz R
Bone Marrow Transplant; 2018 Aug; 53(8):1010-1018. PubMed ID: 29459665
[TBL] [Abstract][Full Text] [Related]
34. Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study.
Okamoto S; Takahashi S; Tanosaki R; Sakamaki H; Onozawa Y; Oh H; Miyawaki S; Kimura Y; Toyama K; Ikeda Y; Asano S
Bone Marrow Transplant; 1996 May; 17(5):679-83. PubMed ID: 8733681
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
36. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
37. Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy.
Kalaycio M; Mendez Z; Pohlman B; Overmoyer B; Boparai N; Jones E; Bolwell B
J Cancer Res Clin Oncol; 1998; 124(5):265-9. PubMed ID: 9645457
[TBL] [Abstract][Full Text] [Related]
38. Timing of administration of dolasetron affects dose necessary to prevent postoperative nausea and vomiting.
Korttila KT; Jokinen JD
J Clin Anesth; 2004 Aug; 16(5):364-70. PubMed ID: 15374558
[TBL] [Abstract][Full Text] [Related]
39. Comparison of oral dolasetron and ondansetron in the prophylaxis of postoperative nausea and vomiting in children.
Karamanlioglu B; Turan A; Memis D; Süt N
Eur J Anaesthesiol; 2003 Oct; 20(10):831-5. PubMed ID: 14580054
[TBL] [Abstract][Full Text] [Related]
40. Pooled analysis of three large clinical trials to determine the optimal dose of dolasetron mesylate needed to prevent postoperative nausea and vomiting. The Dolasetron Prophylaxis Study Group.
Philip BK; McLeskey CH; Chelly JE; McKenzie R; Kovac AL; Diemunsch P; DuBois DM
J Clin Anesth; 2000 Feb; 12(1):1-8. PubMed ID: 10773500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
